Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis.

Intern MedDec 25, 2025 (epub)
Case ReportGastroenterology

Takatoshi Anno, Kazutoshi Murakami, Shuhei Nakanishi et al.

✦ AI-curated · Sources linked

Case in brief

A patient with ulcerative colitis developed severe hypercholesterolemia after starting mesalazine, a first-line treatment for the disease. The report attributed the hypercholesterolemia to mesalazine. An HMG-CoA reductase inhibitor was effective, with marked improvement in the lipid abnormality. The case highlights a potential adverse effect of a medication that may be important to continue for ulcerative colitis.

What made this case unusual

Severe hypercholesterolemia was reported in association with mesalazine, a key first-line ulcerative colitis drug that can be difficult to replace when long-term treatment is needed.

Diagnostic / clinical pearl

Consider mesalazine as a possible contributor when severe hypercholesterolemia develops in a patient with ulcerative colitis.

Source

PubMed · PMID 41443871

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.